Clinical trials: Severe Respiratory Infection
SARS-CoV Infection, COVID-19
Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study
The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to…
- Conditions
- SARS-CoV Infection, COVID-19, Anosmia, Dysgeusia
- Trial name
- NCT04390165
- Testing
- Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
- Where
- 14 sites in Malaysia
- Volunteers
- 498 people
- Sponsor
- Hospital Sultanah Bahiyah
Severe Influenza
Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms
This is a multicenter, randomized, open Label, add-on study.
- Trial name
- NCT03947411
- Testing
- Oseltamivir Phosphate, Xiyanping injection+Oseltamivir Phosphate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Covid19
The Clinical Manifestations of the Severe Acute Respiratory Syndrome, Coronavirus 2( SARS-Cov-2 ); Not Only Pulmonary
A prospective observational study to identify different extrapulmonary clinical manifestations of SARS-CoV-2 and its correlations with the disease severity grades.
- Trial name
- NCT05046509
- Where
- Egypt
- Volunteers
- 445 people
- Sponsor
- Assiut University
Asthma
A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection
A study to investigate if inhaled Interferon beta-1a is safe and tolerated, and can prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of symptoms of common cold or influenza
- Trial name
- INEXAS (NCT02491684)
- Testing
- Interferon beta-1a Nebuliser solution 48 μg/mL
- Where
- 35 sites in Argentina, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Bronchiolitis, Viral
Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis
The purpose of this study is to to demonstrate that a 7-day course of systemic glucocorticoids decreases the inflammatory activity of moderate or severe bronchiolitis in paediatric patients compared to the standard treatment.
- Trial name
- NCT02571517
- Testing
- Glucocorticoids
- Volunteers
- 94 people
- Sponsor
- Fundació Sant Joan de Déu
Sepsis
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.
- Trial name
- NCT00143611
- Testing
- Resatorvid
- Where
- 144 sites in United States, Australia and 15 more
- Volunteers
- 277 people
- Sponsor
- Takeda
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
COVID-19
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
The purpose of this clinical trial is to learn about the safety and immune responses of the study vaccine (called a bivalent BNT162b2 Omicron containing vaccine) in healthy infants and children.
- Trial name
- NCT05630352
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid-19
Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID-19
Patients with Covid-19 (Coronavirus disease 19) may experience multiple neurological symptoms . 18F-FDG PET-CT ( Positons EmissionTomography coupled with a Computer Tomography with flurodesoxyglucose labelled with fluor 18)…
- Trial name
- TEP-COV (NCT04764721)
- Testing
- 18F-FDG PET-CT
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Central Hospital, Nancy, France
Coronavirus Infections
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to person and there is still no…
- Trial name
- NCT04327349
- Testing
- Convalescent Plasma
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Mazandaran University of Medical Sciences
SARS-CoV Infection, COVID-19
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after…
- Trial name
- NCT05886816
- Testing
- Mitoquinone/mitoquinol mesylate
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
COVID-19
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
Evaluation of novel coronavirus induced severe pneumonia by dental pulp mesenchymal stem cells
- Trial name
- NCT04302519
- Testing
- Dental pulp mesenchymal stem cells
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Covid19, Severe Acute Respiratory Syndrome
Ivermectin in Adults With Severe COVID-19.
Since the onset of the disease, more than 40.5 million people have been diagnosed with COVID-19 and nearly 1.2 million people have died (October 21, 2020).
- Trial name
- NCT04602507
- Testing
- Ivermectin
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- CES University
Influenza
Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes
This prespecified analysis will pool the datasets from two pragmatic randomized trials evaluating the relative vaccine effectiveness of high-dose vs.
- Trial name
- FLUNITY-HD (NCT06506812)
- Testing
- High-Dose Influenza Vaccine, Standard-Dose Influenza Vaccine
- Where
- Denmark
- Volunteers
- 466,320 people
- Sponsor
- Tor Biering-Sørensen
Severe Viral Bronchiolitis
Work of Breathing in Bronchiolitis Under Non-invasive Ventilation
Severe acute viral bronchiolitis is the leading cause of pediatric intensive care admission. The first-line recommended ventilation support is continuous positive airway pressure (CPAP), which reduces the work of breathing (WOB)…
- Trial name
- BRONCHIO-VNI (NCT04677556)
- Testing
- Esogastric pressures measurement
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influenza, Acute Lung Injury
Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage
The influenza A/H1N1v pandemic virus causes severe pneumonia that can lead to acute respiratory distress syndrome and death even in healthy young individuals.
- Conditions
- Influenza, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- FluBAL (NCT01089400)
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Corona Virus Infection, SARS-CoV Infection
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
- Conditions
- Corona Virus Infection, SARS-CoV Infection, Coronavirus
- Trial name
- NCT04421664
- Testing
- Hydroxychloroquine
- Where
- 8 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Covid19, Hypoxemia
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Patients with COVID-19 frequently develop lower respiratory complications. Difficulty breathing and a low concentration of oxygen in the blood are of concern in patients with COVID-19, as they indicate that the lungs may be…
- Trial name
- NCT04771000
- Testing
- Ambrisentan
- Where
- 13 sites in Croatia, Spain
- Volunteers
- 88 people
- Sponsor
- Noorik Biopharmaceuticals AG
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
SARS-COV2, Severe Acute Respiratory Syndrome
Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
- Conditions
- SARS-COV2, Severe Acute Respiratory Syndrome, COVID-19
- Trial name
- NCT04320511
- Testing
- CT-V
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Corewell Health East
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.